You are here: Industry Insights > Zolgensma

News List

Study suggests Zolgensma will generate $2.5bn of global sales by 2025 europeanpharmaceuticalreview
April 01, 2020
According to researchers, Zolgensma, made by Novartis, will lead the global spinal muscular atrophy market and generate billions in sales.
Novartis gets positive CHMP opinion for Zolgensma and Cosentyx pharmaceutical-technology
March 31, 2020
Novartis has received a positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) for Zolgensma in spinal muscular atrophy (SMA), and Cosentyx in non-radiographic axial spondyloarthritis (nr-axSpA).
AveXis’ Zolgensma gene therapy yields desired results in SMA trials pharmaceutical-business-review
March 27, 2020
AveXis said that a one-time infusion of Zolgensma (onasemnogene abeparvovec-xioi) delivered rapid, substantial, and clinically meaningful therapeutic benefit ...
Five-year Zolgensma data shows SMA benefit pharmatimes
March 25, 2020
Novartis has released new Zolgensma (onasemnogene abeparvovec-xioi) data, demonstrating rapid, significant and clinically meaningful therapeutic benefit of the drug in patients with spinal muscular atrophy (SMA).
Novartis publishes more positive data for Zolgensma pharmaceutical-technology
March 25, 2020
Novartis subsidiary AveXis presented positive, updated data from three clinical trials of its one-dose gene therapy for spinal muscular atrophy (SMA), Zolgensma.
Novartis Receives Approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma americanpharmaceuticalreview
March 23, 2020
Novartis Pharma announced the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Zolgensma® (onasemnogene abeparvovec).
Novartis gets Japan’s approval for Zolgensma pharmaceutical-technology
March 20, 2020
Novartis Pharma has received the Japanese Ministry of Health, Labour and Welfare (MHLW) approval for Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA).
Novartis' SMA gene therapy Zolgensma could struggle to hit blockbuster territory fiercepharma
September 26, 2019
Novartis has been under pressure ever since the FDA approved Zolgensma in May, and news emerged in August that the company had included inaccurate data in the preclinical package it submitted to the agency.
FDA Approval of Zolgensma Was Based on Manipulated Data drugs
August 08, 2019
The maker of Zolgensma (onasemnogene abeparvovec-xioi) gave manipulated data to the U.S. Food and Drug Administration when it approved the drug, the agency said Tuesday.
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO fiercepharma
July 20, 2019
Gene therapy Zolgensma is under the spotlight as Novartis launches what’s known as the world’s most expensive drug. And now, its chief has offered an early glimpse into the rollout.

Previous page 1 2 3 4 Next page